TMPRSS4 as a Poor Prognostic Factor for Triple-Negative Breast Cancer
AbstractTriple-negative breast cancer (TNBC) is characterized by the lack of immunohistochemical staining for estrogen receptors (ER), progesterone receptors (PR), and lack of overexpression or amplification of human epidermal growth factor receptor 2 (HER2). Our aim was to investigate the expression of transmembrane protease, serine 4 (TMPRSS4) in TNBC patients and its possible relationship to the outcome of the disease. A total of 72 TNBC patients and 109 non-TNBC patients who were diagnosed between 2003 and 2008 were enrolled in this study. Immunohistochemistry was used to compare the expression pattern of TMPRSS4 in TNBC and non-TNBC groups, and the prognostic significance was assessed by Kaplan-Meier analysis and Cox proportional hazards regression in TNBC patients. The rate of high expression of TMPRSS4 was significantly higher in TNBC group than that in non-TNBC group. High expression of TMPRSS4 was significantly correlated with lymph node metastasis, histological grade, and tumor size. TNBC patients with high TMPRSS4 expression showed the poorer overall survival (OS) and disease-free survival (DFS) than those patients with low TMPRSS4 expression. In multivariate analysis, only lymph node metastasis and TMPRSS4 expression were the independent prognostic factors for OS and DFS in TNBC. Our study provides evidence that TMPRSS4 expression is associated with lymph node metastasis, tumor size, and histological grade in TNBC patients, and also is an independent prognostic factor for TNBC. View Full-Text
Share & Cite This Article
Cheng, D.; Kong, H.; Li, Y. TMPRSS4 as a Poor Prognostic Factor for Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2013, 14, 14659-14668.
Cheng D, Kong H, Li Y. TMPRSS4 as a Poor Prognostic Factor for Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2013; 14(7):14659-14668.Chicago/Turabian Style
Cheng, Daye; Kong, Hong; Li, Yunhui. 2013. "TMPRSS4 as a Poor Prognostic Factor for Triple-Negative Breast Cancer." Int. J. Mol. Sci. 14, no. 7: 14659-14668.